Longer-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa

Basit Öğe Kaydı
dc.contributor.authorOkasha, Tarek A.
dc.contributor.authorKucukalic, Abdulah
dc.contributor.authorNasr, Aly Akram A.
dc.contributor.authorZelman, Marek
dc.contributor.authorKaramustafalioglu, Oguz
dc.contributor.authorSir, Aytekin
dc.contributor.authorHarrison, Gavan
dc.date.accessioned2024-04-24T17:14:51Z
dc.date.available2024-04-24T17:14:51Z
dc.date.issued2009
dc.departmentDicle Üniversitesien_US
dc.description5th European-Stanley-Foundation Conference on Bipolar Disease -- OCT 05-07, 2006 -- Barcelona, SPAINen_US
dc.description.abstractObjective: To compare the longer-term outcomes of pharmacological treatment of patients with a diagnosis of bipolar affective disorder currently suffering a manic or hypomanic episode prescribed olanzapine or non-olanzapine medication in naturalistic, clinical practice settings in Bosnia-Herzegovina, Slovakia, Slovenia, Turkey, Saudi Arabia and Egypt. Research design and methods: Prospective, observational, non-interventional study conducted over 9 months. Inpatients or outpatients who initiated or changed oral bipolar mania medication were grouped into (1) those prescribed olanzapine at baseline (n = 569) and (2) those not prescribed olanzapine (n = 325). Main outcome measure(s): The change from baseline in the Clinical Global Impression Severity scale for bipolar disorder (CGI-BP-S), the rates of symptomatic response and remission (based on CGI-BP-S) and the frequency and nature of treatment-emergent adverse events. Analyses included (1) linear or logistic regression, with adjustment for confounders, based on the last observation carried forward and (2) weighted repeated measures models that adjusted for treatment switching and patient drop-out. Results: When results were adjusted for treatment switching and patient drop-out, patients prescribed olanzapine had significantly better CGI-BP-S scores (mean difference = -0.24; 95% confidence interval [CI] -0.33, -0.16; p<0.001) and significantly greater odds of treatment response (odds ratio [OR] = 1.86; 95% CI 1.31, 2.65; p<0.001) and symptom remission (OR 1.65; 95% CI 1.18-2.32; p = 0.003) than those not prescribed olanzapine. The frequency of most adverse events decreased in both groups. Patients prescribed olanzapine had significantly greater weight gain from baseline (mean increase 2.66 kg; 95% CI 2.35, 2.98) compared with those not prescribed olanzapine (mean increase = 1.85 kg; 95% CI 1.51, 2.19; p<0.001). Conclusions: Inclusion of olanzapine is of benefit for pharmacological treatment of patients with bipolar disorder. However, the favourable outcomes observed cannot be directly attributed to olanzapine alone because of the high prevalence of polypharmacy in the patient population.en_US
dc.description.sponsorshipEuropean Stanley Fdnen_US
dc.identifier.doi10.1185/03007990903070270
dc.identifier.endpage1900en_US
dc.identifier.issn0300-7995
dc.identifier.issn1473-4877
dc.identifier.issue8en_US
dc.identifier.pmid19538106
dc.identifier.scopus2-s2.0-67650831186
dc.identifier.scopusqualityQ1
dc.identifier.startpage1889en_US
dc.identifier.urihttps://doi.org/10.1185/03007990903070270
dc.identifier.urihttps://hdl.handle.net/11468/18225
dc.identifier.volume25en_US
dc.identifier.wosWOS:000269930800008
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofCurrent Medical Research and Opinion
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBipolar Disorderen_US
dc.subjectAntipsychotic Agentsen_US
dc.subjectOlanzapineen_US
dc.subjectTreatment Outcomesen_US
dc.titleLonger-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africaen_US
dc.titleLonger-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu